AXSM Stock Advances On CEO’s Pipeline Claim: One New Drug Filing Yearly Through 2030
Axsome Therapeutics (AXSM) shares rose about 5% despite a revenue miss and wider-than-expected loss, driven by strong commercial momentum for its drug AUVELITY and multiple near-term pipeline catalysts. CEO Herriot Tabuteau projected filing one new drug application per year through 2030, with several trials and an FDA decision for AXS-12 expected soon. AUVELITY's sales increased significantly, and demand for other drugs like SYMBRAVO and SUNOSI also saw growth, contributing to positive retail sentiment.
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Rating of "Moderate Buy" from Brokerages
Axsome Therapeutics, Inc. (NASDAQ:AXSM) has received an average "Moderate Buy" rating from twenty-one analysts, with an average 12-month price target of $275.84. Despite this positive outlook, company insiders have sold approximately $12.6 million worth of shares in the past 90 days. The company recently reported a quarterly loss of $0.99 per share, missing consensus estimates, and revenue slightly below analyst forecasts.
AXSOME THERAPEUTICS, INC. : DEUTSCHE BANK CUTS TARGET PRICE TO $267 FROM $280
Deutsche Bank has reduced its target price for Axsome Therapeutics, Inc. from $280 to $267. This information was reported by Reuters. The article itself is primarily a news headline wrapper on a financial platform.
Can Axsome Therapeutics (AXSM) Keep Justifying Its Price On Sales?
Axsome Therapeutics' stock has seen significant gains, leading to questions about whether its current share price is justified by its sales. The company's stock trades at a premium with a P/S ratio of 12.6x compared to an industry average of 4.9x, despite recent positive data from Psych Congress 2026 on Alzheimer's agitation and major depressive disorder treatments. While narratives suggest the stock is undervalued, investors are encouraged to consider the company's growth profile, management incentives, and financial situation alongside its sales performance.
Axsome Therapeutics Is Maintained at Buy by Deutsche Bank
Deutsche Bank has reiterated its Buy rating on Axsome Therapeutics. This indicates a continued positive outlook from the bank regarding the company's stock performance. The article implies that Deutsche Bank maintains its confidence in Axsome Therapeutics.
EBITDA per share of Axsome Therapeutics, Inc. – HAN:19X
This page provides financial data, specifically "EBITDA per share," for Axsome Therapeutics, Inc. (HAN:19X) on the TradingView platform. The content notes that the market is closed and no trades have occurred.
Deutsche Bank Lowers Price Target on Axsome Therapeutics to $267 From $280, Keeps Buy Rating
Deutsche Bank has adjusted its price target for Axsome Therapeutics (AXSM) to $267, down from $280, while maintaining a Buy rating on the stock. This update comes as Axsome Therapeutics currently holds an average rating of Buy with a mean price target of $282.52 across analysts. The full MT Newswires article requires a premium subscription to access.
Pretax income of Axsome Therapeutics, Inc. – HAN:19X
This page from TradingView provides financial information for Axsome Therapeutics, Inc. (HAN:19X), specifically focusing on its pretax income. It offers a general overview of the company's financials on the Hannover Stock Exchange. The content is primarily a shell for displaying financial data and includes various links related to TradingView's platform and services.
Axsome Therapeutics options flow shows heavy put skew ahead of binary catalyst
Options trading for Axsome Therapeutics (AXSM) shows a significant put skew, with 92.7% of today's volume being put options, suggesting a strong bearish sentiment among traders. The dominant trade is a large ratio put spread expiring on October 16, 2026, targeting a price near $170. This bearish positioning comes amidst a recent stock decline, upcoming Phase III readout for ENGAGE, and previous stock sales by the CEO, indicating that the options market may be anticipating further downside ahead of a binary catalyst.
Axsome Therapeutics, Inc. Revenue Breakdown – HAN:19X
Axsome Therapeutics, Inc. (HAN:19X) generated €539.63 million in revenue last year, primarily from its Novel Therapies for the Management of Central Nervous System Disorders segment, which contributed €543.63 million. The United States was the largest geographical contributor, accounting for €535.22 million of the company's revenue.
Axsome Therapeutics (NASDAQ:AXSM) Shares Down 5.4% on Analyst Downgrade
Axsome Therapeutics (NASDAQ:AXSM) shares dropped 5.4% after Deutsche Bank lowered its price target from $280 to $267, while still maintaining a buy rating. Despite this downgrade, the stock retains a consensus "Moderate Buy" rating with an average price target of $271. Insider sales amounted to approximately 109,330 shares worth $24.6 million over the last quarter, though institutional investors and hedge funds hold a significant 81.49% stake in the company.
Deutsche Bank Lowers Price Target on Axsome Therapeutics to $267 From $280, Keeps Buy Rating
Deutsche Bank has lowered its price target for Axsome Therapeutics (AXSM) to $267 from $280, while maintaining a "Buy" rating on the stock. The adjustment was reported on September 29, 2026. Axsome Therapeutics is a biopharmaceutical company focusing on central nervous system conditions, with products like AUVELITY, SUNOSI, and SYMBRAVO, and a pipeline including AXS-05, AXS-12, and AXS-14.
Is Axsome Therapeutics (AXSM) Undervalued As Caregiver Survey Data Tests Its CNS Growth Story?
Axsome Therapeutics (AXSM) is presenting new caregiver survey data on Alzheimer’s agitation, yet its share price has recently cooled despite strong longer-term returns. Simply Wall St's analysis suggests Axsome is 31% undervalued, with a fair value estimate of $282.51 against a current price of $195.09, driven by expectations for revenue growth, high earnings, and a robust CNS pipeline. However, potential risks include payer pressure, competition, and liquidity concerns, highlighting the importance of execution for its valuation.
Axsome Therapeutics Is Maintained at Equal-Weight by Morgan Stanley
Morgan Stanley has reiterated its "Equal-Weight" rating for Axsome Therapeutics. This indicates that the firm views the stock's performance as likely to align with the broader market.
AXSM Maintains Rating by Morgan Stanley -- Price Target Lowered to $247
Morgan Stanley analyst Sean Laaman maintained an "Equal-Weight" rating for Axsome Therapeutics (AXSM) but lowered its price target to $247 from $251. This adjustment reflects a cautious outlook amidst a competitive biotechnology landscape. Despite strong momentum and interest from institutional investors, the company's low profitability, financial strength, and high forward P/E ratio suggest potential concerns for investors.
AXSOME THERAPEUTICS, INC. : TRUIST SECURITIES ASSUMES COVERAGE WITH BUY RATING; TARGET PRICE $285 VS $200
Truist Securities has initiated coverage on Axsome Therapeutics, Inc. with a "Buy" rating. The firm has set a new target price of $285 for the company's stock, which represents a significant increase from the previous target of $200. This upgrade suggests a strong positive outlook from Truist Securities regarding Axsome Therapeutics' future performance.
AXSM Stock Price and Chart — NASDAQ:AXSM
Axsome Therapeutics, Inc. (NASDAQ: AXSM) stock is down -0.48% today, with Morgan Stanley recently cutting its price target from $251 to $247 while maintaining a "Neutral" rating. The company, which focuses on central nervous system disorders, has seen its stock increase 64.65% over the past year and has a market capitalization of $10.22 billion. Analysts have a wide forecast for AXSM, with price targets ranging from $246.00 to $380.00.
H.C. Wainwright reiterates Axsome stock Buy rating at $290 target By Investing.com
H.C. Wainwright has reiterated a Buy rating and a $290 price target for Axsome Therapeutics (NASDAQ:AXSM) following the release of survey results regarding Alzheimer’s agitation. The survey, sponsored by Axsome, highlighted the significant impact of agitation on Alzheimer's patients and caregivers, revealing a strong desire for better symptom tracking and treatment options. This reiteration comes as Axsome reported strong Q2 2026 revenues and positive analyst sentiment, with several firms adjusting price targets upwards, reflecting optimism about the company's growth, particularly with its drug Auvelity.
$100 Invested In Axsome Therapeutics 10 Years Ago Would Be Worth This Much Today
This article calculates the return on a hypothetical $100 investment in Axsome Therapeutics (NASDAQ: AXSM) made 10 years ago. An initial investment of $100 would now be worth $2,555.80 due to an average annual return of 37.87%, outperforming the market by 24.39% annually. The piece highlights the significant impact of compounded returns over time.
Truist Securities maintains Buy rating on Axsome Therapeutics, $285 price target
Truist Securities has reiterated its Buy rating on Axsome Therapeutics (AXSM) with a price target of $285.00, implying a 40.3% upside. The rating is supported by Axsome's strong revenue growth, evidenced by a 46% year-over-year increase in net product revenue for Q2 2026, driven by the successful launch of Auvelity. The company also has a de-risked pipeline with multiple catalysts expected within the next 12-18 months.
Truist initiates Axsome stock coverage with buy rating on growth
Truist Securities has initiated coverage on Axsome Therapeutics Inc. (NASDAQ:AXSM) with a buy rating and a price target of $285, indicating a 40% upside. The firm highlighted Axsome's strong near-term revenue growth projections, impressive gross profit margins, and a pipeline with reduced clinical risk, especially following the approval of Auvelity for major depressive disorder. InvestingPro analysis suggests the company is undervalued, with other firms like H.C. Wainwright, Mizuho, RBC Capital, Needham, and Guggenheim also maintaining positive outlooks and price targets due to Auvelity's performance and pipeline developments.
Axsome Therapeutics, Inc. (AXSM) Stock Analysis: Promising 37% Upside Potential Amidst Strong Buy Ratings
Axsome Therapeutics (AXSM) is a biotechnology company focused on CNS disorders, showing a promising 37% upside potential with an average target price of $285.42 and 20 buy ratings from analysts. Despite current negative EPS and free cash flow due to reinvestment, its robust pipeline and strategic collaborations, like with Duke University for smoking cessation research, position it as a compelling opportunity for growth-oriented investors in the biotech sector. The company's innovative product lineup, including Auvelity and Sunosi, addresses significant unmet medical needs.
Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026
Axsome Therapeutics presented ten posters at Psych Congress 2026, showcasing new data and findings across its psychiatry and neurology pipeline. The presentations covered Alzheimer's disease agitation, major depressive disorder, excessive daytime sleepiness in narcolepsy and OSA, and narcolepsy, highlighting various aspects from clinical burden to treatment effects. These presentations reinforce Axsome's commitment to addressing critical gaps in CNS disorder treatment through scientific breakthroughs.
Three in four caregivers wish they had recognized Alzheimer’s agitation sooner
A survey by Axsome Therapeutics found that 97% of caregivers reported Alzheimer’s agitation negatively impacted their loved one's quality of life, and 76% wished they had recognized symptoms sooner. Many caregivers expressed a need for better symptom tracking tools and treatments without negative side effects. The results underscore significant unmet needs in the recognition and management of Alzheimer’s disease agitation.
Axsome Therapeutics Announces Results of the Shared Goals
Axsome Therapeutics announced the results of its "Shared Goals: Navigating Alzheimer's Agitation" survey, highlighting that agitation in Alzheimer's disease is often recognized late, significantly disrupting daily life and negatively impacting patients' quality of life. The survey, conducted with The Harris Poll and CaringKind, found that 97% of care partners reported negative impacts on loved ones' quality of life, and 76% wished they had recognized symptoms sooner. Care partners also expressed a need for better tracking tools and effective medications without negative side effects.
Axsome Therapeutics (AXSM) Presents Fresh Psych Congress Data, Is The Stock Cheap?
Axsome Therapeutics (AXSM) recently presented new data at Psych Congress 2026 for major depressive disorder and Alzheimer’s disease agitation, drawing attention to its pipeline. Despite short-term stock fluctuations, long-term performance has been strong. The company is currently trading at a significant discount to its estimated intrinsic value and analyst targets, raising questions about whether it is mispriced or if the valuation reflects execution and earnings risk.
Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference
Axsome Therapeutics (NASDAQ: AXSM) presented at the H.C. Wainwright 28th Annual Global Investment Conference, detailing strong growth for its commercial products, especially Auvelity, which is a major driver of revenue. The company expanded its sales force significantly to support the new Alzheimer’s disease agitation indication for Auvelity and highlighted the continued growth of Sunosi and SYMBRAVO. Axsome also discussed its robust pipeline with several late-stage programs and a strong financial position, approaching cash-flow positivity.
Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference
Axsome Therapeutics highlighted the growth of its commercial portfolio, particularly Auvelity, Sunosi, and SYMBRAVO, during the H.C. Wainwright 28th Annual Global Investment Conference. The company announced an expanded sales force to support Auvelity's new Alzheimer's disease agitation indication, along with progress in its late-stage clinical pipeline and a strong financial position with $320 million in cash. Axsome expects to approach cash-flow positivity and potentially achieve profitability, with several NDA filings anticipated annually.
Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference
Axsome Therapeutics discussed significant growth in its commercial portfolio, an expanded sales force, and progress in its late-stage clinical programs at the H.C. Wainwright 28th Annual Global Investment Conference. The company highlighted the commercial success and potential of Auvelity, particularly with its new indication for Alzheimer's disease agitation, and provided updates on other products like Sunosi and SYMBRAVO. Axsome also outlined its robust pipeline, ongoing clinical trials, and strong financial position, expecting approximately one NDA filing annually through 2031.
Bank of America Corp DE Acquires Shares of 452,491 Axsome Therapeutics, Inc. $AXSM
Bank of America Corp DE has acquired 452,491 shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) for approximately $110.8 million, representing a 0.86% stake in the company. Despite a recent quarterly loss and revenue slightly below expectations, institutional investors and hedge funds collectively own 81.49% of Axsome, with analysts maintaining a "Moderate Buy" rating. However, company insiders have sold a significant number of shares, totaling over $24.6 million in the last quarter.
Axsome Therapeutics (AXSM) Reported New Clinical Data In Depression And Alzheimer’s Agitation
Axsome Therapeutics (AXSM) announced new clinical data for its depression and Alzheimer's agitation programs at a psychiatry congress, reinforcing its central nervous system pipeline. These findings are expected to guide future study designs and regulatory discussions, supporting the company's strategy for a diversified revenue base from multiple indications. The report emphasizes the importance of these clinical details for Axsome's growth thesis and its ability to compete against larger pharmaceutical companies.
Analysts Think Axsome Therapeutics Stock Could Soar 35% Over the Next 12 Months. Is the Stock a No-Brainer Buy?
Analysts predict Axsome Therapeutics (AXSM) stock could rise 35% over the next year due to strong financial results, including a 46% year-over-year revenue increase in Q2, primarily driven by its depression medicine Auvelity. The company also has multiple catalysts on the horizon, such as label expansion for Auvelity in Alzheimer's disease agitation, and ongoing Phase 3 trials for AXS-14 and AXS-20. Despite near-term stock volatility, the company's robust late-stage pipeline suggests strong medium-to-long-term growth potential, making it an attractive long-term investment, though it was not among The Motley Fool's top 10 current stock picks.
Baird Financial Group Inc. Acquires New Holdings in Axsome Therapeutics, Inc. $AXSM
Baird Financial Group Inc. has acquired a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM), purchasing 10,202 shares valued at approximately $2.5 million during the second quarter. Despite Axsome Therapeutics reporting a quarterly loss and missing revenue expectations, analysts maintain a "Moderate Buy" rating with a consensus price target of $267.60. Insider selling has also been noted, with executives offloading shares worth over $24 million in the last 90 days.
Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026
Axsome Therapeutics announced the presentation of ten posters at Psych Congress 2026, showcasing new data and encore data across its psychiatry and neurology portfolio. The presentations include new findings in major depressive disorder and Alzheimer's disease agitation, along with additional data on excessive daytime sleepiness in narcolepsy and OSA, and narcolepsy with cataplexy. These presentations highlight the company's commitment to addressing critical gaps in central nervous system disorder treatments.
Engineers Gate Manager LP Has $2.74 Million Position in Axsome Therapeutics, Inc. $AXSM
Engineers Gate Manager LP significantly reduced its stake in Axsome Therapeutics (NASDAQ:AXSM) by 31.7% in the second quarter, selling 5,186 shares but still holding 11,198 shares valued at $2.74 million. Despite this reduction, institutional ownership remains high at 81.49%, with major firms like California State Teachers Retirement System and BlackRock making substantial new investments. Analysts maintain a "Moderate Buy" rating for Axsome, with an average price target of $267.60, even after the company missed recent quarterly EPS and revenue estimates.
Axsome Therapeutics Inc (19X) Q4 2023 Earnings Report - Results, Call & Slides
Axsome Therapeutics Inc (19X) has released its Q4 2023 earnings report. The company missed consensus EPS by -€0.78 with an actual EPS of -€1.79, but beat revenue expectations by +€1.97M, reporting actual revenue of €61.60M, marking a 193.50% YoY growth. The earnings call was held on February 20, 2024, and the next earnings report is estimated for November 9, 2026.
Axsome Therapeutics, Inc. $AXSM Shares Bought by California State Teachers Retirement System
The California State Teachers Retirement System significantly increased its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 27,073.3% in the second quarter, now owning 11.17 million shares valued at approximately $2.74 billion. Despite a recent earnings miss and insider share sales, analysts maintain a "Moderate Buy" rating with an average target price of $267.60. The company focuses on developing therapies for central nervous system disorders.
Axsome Therapeutics Inc (19X) Q4 2025 Earnings Report - Results, Call & Slides
Axsome Therapeutics Inc (19X) has released its Q4 2025 earnings report, exceeding analyst expectations. The company reported an actual EPS of -€0.48 against a consensus of -€0.59, and actual revenue of €167.79M, surpassing the expected €165.53M with a 65.03% year-over-year growth. The earnings call took place on February 23, 2026, and the next earnings date is estimated for November 9, 2026.
Hsbc Holdings PLC Sells 12,653 Shares of Axsome Therapeutics, Inc. $AXSM
Hsbc Holdings PLC reduced its stake in Axsome Therapeutics, Inc. by 18.5% in the second quarter, selling 12,653 shares and retaining 55,800 shares valued at $13,667,000. Other institutional investors also adjusted their positions in Axsome, which has a "Moderate Buy" consensus rating from analysts with an average target price of $267.60. The article also details recent insider stock sales by the CEO and COO, highlighting significant decreases in their ownership.
33,554 Shares in Axsome Therapeutics, Inc. $AXSM Bought by Readystate Asset Management LP
Readystate Asset Management LP has acquired 33,554 shares of Axsome Therapeutics (NASDAQ:AXSM) for approximately $8.2 million, now holding a 0.06% stake in the company. Despite Axsome missing Q2 earnings and revenue estimates, institutional investors collectively own 81.49% of AXSM, and analysts maintain a "Moderate Buy" rating with an average price target of $267.60. Recent insider selling has also been noted, primarily to cover tax obligations.
Seven Fleet Capital Management LP Grows Stock Position in Axsome Therapeutics, Inc. $AXSM
Seven Fleet Capital Management LP significantly increased its stake in Axsome Therapeutics, Inc. by 105.1% in the second quarter, now holding 28,826 shares valued at $7.1 million. Despite Axsome missing analyst estimates for both earnings and revenue, the stock maintains a "Moderate Buy" consensus rating with an average price target of $267.60. Institutional investors collectively own 81.49% of the company's stock, while insiders have recently sold shares, primarily for tax withholding.
12,293 Shares in Axsome Therapeutics, Inc. $AXSM Bought by Public Employees Retirement System of Ohio
The Public Employees Retirement System of Ohio acquired 12,293 shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) valued at approximately $3.0 million during the second quarter. This purchase contributes to institutional investors now owning 81.49% of the company's stock. Despite a recent quarterly loss and insider selling, analysts maintain a "Moderate Buy" consensus rating for Axsome, with an average price target of $267.60.
Corient Private Wealth LP Makes New $1.26 Million Investment in Axsome Therapeutics, Inc. $AXSM
Corient Private Wealth LP has made a new investment of $1.26 million in Axsome Therapeutics by acquiring 5,156 shares in the second quarter. This move contributes to institutional investors and hedge funds now owning 81.49% of AXSM's outstanding stock. Despite the company reporting a quarterly loss of $0.99 per share and recent insider stock sales totaling $44.8 million, analysts maintain a "Moderate Buy" rating with an average price target of $267.60.
Axsome therapeutics COO Mark Jacobson sells $2.08m of company stock
Axsome Therapeutics COO Mark Jacobson sold 10,000 shares of common stock for over $2 million after exercising stock options. This transaction was pre-approved, and Jacobson now directly holds no common stock but retains over 100,000 derivative securities. The sale follows a 67% increase in AXSM shares over the past year and comes amid positive financial results for Axsome, with analysts adjusting price targets based on drug performance and strategic initiatives.
Axsome Therapeutics, Inc. $AXSM Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
UBS Asset Management increased its stake in Axsome Therapeutics (NASDAQ:AXSM) by 34% in the second quarter, bringing its total holding to 127,178 shares valued at $31.1 million. Despite a quarterly loss and revenue miss, analysts maintain a "Moderate Buy" rating with an average price target of $267.60. Institutional investors now own 81.49% of the company, while insiders have recently sold shares.
Axsome Therapeutics (NASDAQ:AXSM) COO Sells $2,086,500.00 in Stock
Axsome Therapeutics COO Mark Jacobson sold 10,000 shares of the company's stock for $2,086,500.00, reducing his direct ownership by 50%. The transaction occurred on Thursday, September 3rd, with the stock priced at $208.65 per share. Despite missing recent quarterly earnings and revenue expectations, institutional investors hold a significant stake, and analysts maintain a "Moderate Buy" rating with an average price target of $267.60.
Van ECK Associates Corp Has $7.17 Million Position in Axsome Therapeutics, Inc. $AXSM
Van ECK Associates Corp has reduced its stake in Axsome Therapeutics by 22.2%, now holding 29,309 shares valued at $7.17 million. Despite this reduction and a recent earnings miss, analysts maintain a "Moderate Buy" rating for Axsome with an average price target of $267.60. The company's stock opened at $202.83, below its 52-week high, while institutional investors collectively own 81.49% of the shares.
Legal & General Group Plc Makes New $8.10 Million Investment in Axsome Therapeutics, Inc. $AXSM
Legal & General Group Plc has made a new $8.10 million investment in Axsome Therapeutics, Inc. by purchasing 33,072 shares. This comes as Axsome Therapeutics reported a quarterly loss and missed revenue estimates, yet analyst sentiment remains positive with a "Moderate Buy" rating. Insider transactions show recent sales by company directors to cover tax obligations.
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Axsome Therapeutics, Inc. announced its participation in several upcoming investor conferences in September 2026, including the Wells Fargo, Cantor Global, Morgan Stanley Global, Baird Global, H.C. Wainwright Global Investment Conferences, and the Deutsche Bank Healthcare Summit. The company will conduct fireside chats and investor meetings to discuss its advancements in central nervous system disorders. Live webcasts and replays of most sessions will be available on Axsome's investor relations website.
Wellington Management Group LLP Has $160.06 Million Holdings in Axsome Therapeutics, Inc. $AXSM
Wellington Management Group LLP significantly reduced its stake in Axsome Therapeutics by 42.9% in the second quarter, now holding 653,920 shares valued at approximately $160.1 million. This comes as Axsome insiders, including the CEO and CFO, have also sold a substantial number of shares totaling over $42 million in the last 90 days. Despite missing recent quarterly earnings and revenue estimates, analysts maintain a "Moderate Buy" rating with an average target price of $267.60 for Axsome Therapeutics.
